Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04594590 · ClinicalTrials.gov registry record
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
A clinical trial, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- 9
- Enrollment target
NCT04594590: Completed study, sponsored by State University of New York at Buffalo.
NCT04594590 is a clinical trial that has completed, run by State University of New York at Buffalo. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04594590 has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
The purpose of the study is to systematically characterize the clinical course of the progressive neuropathy and optic atrophy observe in pediatric and adult patients with biallelic mutations in the solute carrier family 25 member 46 (SLC25A46) gene.
Primary Outcome
In addition to a standard medical history, patients or their legal guardians will be asked to complete a custom medical history questionnaire tailored toward conditions commonly observed in patients with biallelic SLC25A46 mutations. The items that will be asked about in this questionnaire are as follows: 1. Known mutations in SLC25A46 2. Any family history of illness 3. Complications of pregnancy 4. Premature birth 5. Complications with birth 6. Developmental delay 7. Developmental regression
Interventions
- GENETIC Mutation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-11-03 |
| Est. Completion | 2023-08-17 |
What the finished NCT04594590 record still lists
NCT04594590 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Mutation analysis is the first listed.
NCT04594590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04594590 about?
NCT04594590 is a clinical study titled "Natural History Study of SLC25A46 Mutation-related Mitochondriopathy". The purpose of the study is to systematically characterize the clinical course of the progressive neuropathy and optic atrophy observe in pediatric and adult patients with biallelic mutations in the solute carrier family 25 member 46 (SLC25A46) gene.
What is the current status of trial NCT04594590?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2020-11-03. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT04594590?
The interventions under investigation include: Mutation analysis (GENETIC).
Who is sponsoring clinical trial NCT04594590?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI